An observational study in Pediatric Cancer and Survivorship, sponsored by Giselle Sholler. Recruiting at 18 sites in United States. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Giselle Sholler · Observational
This is an observational data registry study of pediatric cancer patients at participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
This observational registry and banking study is being performed on a large cohort of subjects who have received molecular testing to better understand the relationship between genomic and molecular information and clinical outcomes, and to enable timely and informed treatment decisions by physicians for their cancers. We hypothesize that large gene panels, sequencing (DNA/RNA), and epigenetics of tumors can identify molecular aberrations that can be leveraged to offer more effective treatment. Findings may highlight additional areas of research required to better understand the molecular underpinnings of the relationship between molecular abnormalities and disease. Banked specimens and the creation of tumor cell lines and xenograft models will facilitate further advancement of this research.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Giselle Sholler is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pediatric cancer subjects, survivorship, and healthy volunteers at The Pennsylvania State University and participating Beat Childhood Cancer Research Consortium sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects that fit into one of the following categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with suspected or confirmed pediatric solid tumors
Other: No intervention- registry only
No intervention- registry only
Create a data registry of clinical and molecular/genomic data
Create a data registry of clinical and molecular/genomic data from cancer patients who have undergone biopsy or surgical resection for clinical care to better understand the relationship between genomic and molecular information and clinical outcomes.
Time frame: 10 Years
Determine number and types of genomic alterations within tumor types/subtypes
Define genomic landscape of pediatric cancers through the determination of the number and types of genomic alterations within tumor types/subtypes, across tumor types, and tumor evolution over time.
Time frame: 10 Years
Evaluate the rate of actionable genomic alternations
Evaluate the rate of actionable genomic alternations resulting in associated targeted therapies relative to all actionable genomic alterations.
Time frame: 10 Years
Evaluate the correlation of baseline genomic alterations with clinical outcome.
Evaluate the correlation of baseline genomic alterations with clinical outcome.
Time frame: 10 Years
Identify biomarkers that predict risk of adverse outcomes that occur following pediatric cancer therapy.
Identify biomarkers that predict risk of adverse outcomes that occur following pediatric cancer therapy.
Time frame: 10 Years
Bank additional specimens available for future research projects
Bank additional specimens available for future research projects
Time frame: 10 Years
Develop cell line and xenograft models of pediatric cancers for future research
Develop cell line and xenograft models of pediatric cancers for future research
Time frame: 10 Years
Identify biomarkers that predict risks of disease states in subject controls that did not receive cancer therapy.
Identify biomarkers that predict risks of disease states in subject controls that did not receive cancer therapy.
Time frame: 10 Years
Identify biomarkers that may predict risk of disease dependent on sex, race, ethnicity, or the presence of comorbidities.
Identify biomarkers that may predict risk of disease dependent on sex, race, ethnicity, or the presence of comorbidities.
Time frame: 10 Years
Not enrolling at this site.
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Giselle Sholler